LPC investigates its own chair over racism and discrimination claims

A Hampshire-based LPC is investigating its chair after claims of discriminatory and potentially racist behaviours were lodged by a member of the committee, C+D has learned.

exclusive
Investigations_shutterstock_325249880_620x413.jpg
Deborah Crockford: The LPC "takes this type of issue very seriously"

A member of the Community Pharmacy South Central (CPSC) local pharmaceutical committee (LPC) – who wished to remain anonymous – lodged a complaint against the LPC’s chair, Ashley Littlewood-Miller, after feeling they had been discriminated against on the basis of their ethnicity, they told C+D.

CPSC CEO Deborah Crockford told C+D that the LPC “takes this type of issue very seriously and [is] giving it the time and attention that it deserves”.

“We are conducting an investigation and, once that is concluded, the committee will take any necessary remedial action,” Ms Crockford added.

Mr Littlewood-Miller “firmly” denies “the accusations made against [him] and will continue to assist the LPC with its ongoing investigation”, he told C+D.

The triggering episode

The anonymous committee member claimed that Mr Littlewood-Miller had started treating them differently after they had asked for some financial information in 2019, which they were under the impression should have been visible to LPC members.

Mr Littlewood-Miller had allegedly “aggressively” prevented them from obtaining the information, according to the committee member.

They said that, having appointed some barristers at their own expense to review the LPC constitution, they were told it was their right to obtain the information they had requested.

The committee member told C+D of more episodes where they believed they had faced racial discrimination, claiming that Mr Littlewood-Miller would not have adopted the same type of behaviour with other committee members.

They argued the chair’s behaviours were racially motivated, as their look “clearly identifies” them as an ethnic minority.

“I was being racially abused during my school days and I know what it feels like and what it looks like,” they said.

The committee member believes the LPC has been slow in handling their case and told C+D that the chair should have stepped down while he was being investigated. However, Mr Littlewood-Miller remains in post.

An email seen by C+D shows that, while the LPC had reached a conclusion on the case last month (June 29), that decision had to be withdrawn as the whole committee had not been consulted on it.

C+D awaits the outcome of the investigation.

In an effort to investigate whether pharmacy professionals' experience of racism in pharmacy had changed over the past 12 months, C+D has hosted a webinar – which you can now rewatch – entitled Racism in pharmacy – what's changed and what's next?

Sign in or register for free

Latest from News

‘Smaller than usual’ PQS reinstated under new funding deal

 
• By 
 • comment

The government has announced that the pharmacy quality scheme (PQS) will be “reinstated” in 2025/26 as part of the new funding deal but is “smaller than usual”.

Government to ‘review’ margin system and faster Cat M process

 
• By 
 • comment

The new pharmacy funding deal has revealed incoming changes to the medicines margin, including plans for an “early entry” Category M process.

Pharmacies can ‘change’ core hours under new contract

 
• By 
 • comment

The government has announced that pharmacies in England will be able to undergo an “application process” to change the days and times of their core opening hours to “better serve their patients”.

More from Politics

New evidence Brexit caused UK medicines shortages

 
• By 
 • comment

A health and social care think tank has revealed that the “elevated and troubling level” of medicine shortages in the UK can be blamed on Brexit.

Risk pharmacies ‘deprioritised’ if GP role grows, report warns

 
• By 
 • comment

A Westminster think tank has said that the government’s proposed Neighbourhood Health Service, which plans to scale up general practice, could put community pharmacies at risk of being “deprioritised”.